March 16 (Reuters) - Cogent Biosciences Inc COGT.O:
COGENT BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM)
COGENT BIOSCIENCES: BEZUCLASTINIB PDUFA TARGET ACTION DATE SET FOR DEC 30, 2026